M&A and Life SciencesIndustry advantage |
|
By 2012 drugs representing over $74 billion in sales will lose patent protection and therefore face the possibility of competition from generic manufacturers. This “patent cliff,” combined with the current uncertainty surrounding healthcare reform, is causing pharmaceutical companies to revaluate their business development strategies. Learn how the issues facing life sciences companies differ significantly from other sectors. Below we have provided resources and materials designed to help you in your efforts to minimize your risks and maximize your returns.
Learn more with our industry specialist video.
Featured content
 |
Videocast: Life sciences and emerging markets |
 |
Acquisitions versus product development: An emerging trend in life sciences This piece, based on insights from Deloitte recap, helps pharmaceutical and biotech executives understand factors driving the industry to later-stage deals. |
|
|
A conversation with Phil Pfrang 2008 Directorship Healthcare Life Sciences interview with Phil Pfrang national health care and life sciences industry leader. |
Stay updated
Subscribe to receive updates from Deloitte's Merger & Acquisition practice:
E-mail
As used in this document, “Deloitte” means Deloitte LLP and its subsidiaries. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.
